Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 15/20 | 0.57 |
| ▸ | INSR | P06213 | 10/20 | 0.55 |
| ▸ | IGF1R | P08069 | 9/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | STK10 | O94804 | 2/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620280 | 1.00 | EGFR (0.60) | EGFRMAPK3ALKINSRIGF1R | |
| SCHEMBL24620619 | 0.93 | ALK (0.64) | EGFRMAPK3ALKINSRIGF1R | |
| SCHEMBL29791360 | 0.93 | ALK (0.64) | EGFRMAPK3ALKINSRIGF1R | |
| SCHEMBL30833043 | 0.93 | MAPK3 (0.66) | EGFRMAPK3ALK | |
| SCHEMBL24620313 | 0.93 | MAPK3 (0.66) | EGFRMAPK3ALK | |
| SCHEMBL24620475 | 0.92 | ALK (0.55) | EGFRMAPK3ALKPLK1ULK1 | |
| SCHEMBL30833045 | 0.92 | ALK (0.58) | EGFRMAPK3ALKINSRIGF1R | |
| SCHEMBL24620208 | 0.92 | ALK (0.58) | EGFRMAPK3ALKINSRIGF1R | |
| SCHEMBL29791454 | 0.92 | ALK (0.55) | EGFRMAPK3ALKPLK1ULK1 | |
| SCHEMBL24620234 | 0.91 | ALK (0.56) | EGFRMAPK3ALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | claimed |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | EGFR 1022/4885MAPK3 387/4885ALK 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.